GSK
GSK plc (NYSE: GSK) announced the FDA approved Jideytro (zidesamtinib) for the treatment of locally...
Article Summary
HOLD- GSK plc (NYSE: GSK) announced the FDA approved Jideytro (zidesamtinib) for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer patients who received a prior ROS1 kinase inhibitor, with the approval coming ahead of the original target action date of 18 September 2026 and following FDA's Breakthrough Therapy and Orphan Drug Designations.
- GSK Plc ADR announced the approval based on results from the global ARROS-1 phase I/II clinical trial showing meaningful and durable responses including in patients with brain metastases and ROS1 resistance mutations, with objective response rate of 44% (95% confidence interval 34-53%) and duration of response rates at six and 12 months at 82% and 69% respectively.
- The most common adverse reactions in pooled safety population included oedema, peripheral neuropathy, constipation, fatigue and dyspnoea.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 9.2% | 25% | 35.0 ptsBelow Screener (9.2%) - Weak growth |
| EPS Growth Next 5Y ? | 5.3% | 25% | 20.0 ptsWeak (5.3%) - Low expectations |
| Target Price Upside ? | 14.3% | 20% | 50.0 ptsMeets Minimum (14.3%) - Target: $58.00 vs Current: $50.76 |
| Gross Margin % ? | 72.8% | 15% | 100.0 ptsExceptional (72.8%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -17.7% | 15% | 40.0 ptsMild Pullback (-17.7%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About GSK
- GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
- It operates through Commercial Operations and Total R&D segments.
- The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.
- It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus.
- Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions.
- It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.
- It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression.
- The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB.
- GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022.
- The company was founded in 1715 and is headquartered in London, United Kingdom.